MCID: STM006
MIFTS: 47

Stomach Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Stomach Disease

MalaCards integrated aliases for Stomach Disease:

Name: Stomach Disease 12 15 17
Stomach Diseases 44 71
Gastropathy 12 54
Stomach Disorders 42
Stomach Disorder 12
Gastric Disorder 54
Gastric Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:76
MeSH 44 D013272
NCIt 50 C26886
SNOMED-CT 67 196598004
UMLS 71 C0038354

Summaries for Stomach Disease

MedlinePlus : 42 Your stomach is an organ between your esophagus and small intestine. It is where digestion of protein begins. The stomach has three tasks. It stores swallowed food. It mixes the food with stomach acids. Then it sends the mixture on to the small intestine. Most people have a problem with their stomach at one time or another. Indigestion and heartburn are common problems. You can relieve some stomach problems with over-the-counter medicines and lifestyle changes, such as avoiding fatty foods or eating more slowly. Other problems like peptic ulcers or GERD require medical attention. You should see a doctor if you have any of the following: Blood when you have a bowel movement Severe abdominal pain Heartburn not relieved by antacids Unintended weight loss Ongoing vomiting or diarrhea NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Stomach Disease, also known as stomach diseases, is related to active peptic ulcer disease and peptic ulcer disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Stomach Disease is DDX21 (DExD-Box Helicase 21), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Rebamipide and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include stomach, small intestine and liver.

Disease Ontology : 12 A gastrointestinal system disease that is located in the stomach.

Wikipedia : 74 Stomach diseases include gastritis, gastroparesis, Crohn's disease and various... more...

Related Diseases for Stomach Disease

Diseases related to Stomach Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 349)
# Related Disease Score Top Affiliating Genes
1 active peptic ulcer disease 30.9 PTGS2 HRH2
2 peptic ulcer disease 30.6 PTGS2 HRH2 GHRL
3 gastric cancer 30.6 TIMP1 PTGS2 MMP7 MIR9-1 MIR30A MIR21
4 esophageal cancer 30.5 TIMP1 PTGS2 MMP7 MIR9-1 MIR30A MIR21
5 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.5 PTGS2 HRH2
6 leukemia, acute lymphoblastic 30.4 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR149
7 pulmonary disease, chronic obstructive 30.3 TIMP1 MIR21 MIR199A1 MIR17
8 periodontitis 30.3 TIMP1 PTGS2 MIR21 MIR125A
9 gastrointestinal system disease 30.2 MIR9-1 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
10 hernia, hiatus 30.2 HRH2 GHRL
11 peptic esophagitis 30.1 PTGS2 HRH2
12 gastritis, familial giant hypertrophic 11.3
13 functional gastric disease 11.1
14 non-hypoproteinemic hypertrophic gastropathy 11.1
15 gastritis 10.8
16 esophagus adenocarcinoma 10.6 PTGS2 MIR21 MIR199A1 MIR196A1 MIR145 MIR143
17 tongue disease 10.6 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
18 cervix small cell carcinoma 10.6 MIR199A1 MIR145 MIR143
19 intestinal benign neoplasm 10.6 PTGS2 MIR21 MIR20A MIR199A1 MIR196A1 MIR17
20 leukocyte disease 10.6 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR125A
21 gastrointestinal system benign neoplasm 10.6 PTGS2 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
22 ovarian serous carcinoma 10.6 MIR21 MIR20A MIR199A1 MIR145 MIR143 MIR125A
23 autoimmune disease of musculoskeletal system 10.6 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR125A
24 retinal vascular disease 10.6 MIR30A MIR21 MIR20A MIR199A1 MIR17
25 rectum cancer 10.6 MMP7 MIR21 MIR20A MIR17 MIR145 MIR143
26 inherited metabolic disorder 10.6 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
27 cell type benign neoplasm 10.6 PTGS2 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
28 gallbladder disease 10.6 MIR199A1 MIR196A1 MIR17 MIR145 MIR143
29 bone inflammation disease 10.6 PTGS2 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
30 colorectal adenoma 10.6 PTGS2 MMP7 MIR21 MIR17
31 cerebral arterial disease 10.6 MIR199A1 MIR145 MIR143 MIR125A
32 mature b-cell neoplasm 10.6 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR125A
33 bile duct disease 10.6 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR17 MIR145
34 overnutrition 10.6 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR125A
35 malignant ovarian surface epithelial-stromal neoplasm 10.6 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
36 biliary tract disease 10.6 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR17 MIR145
37 bile duct adenocarcinoma 10.6 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
38 ovary epithelial cancer 10.6 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
39 endometriosis 10.6 TIMP1 PTGS2 MMP7 MIR20A MIR199A1 MIR145
40 infratentorial cancer 10.6 MIR9-1 MIR20A MIR199A1 MIR196A1 MIR17
41 bone marrow cancer 10.6 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
42 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.6 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR125A
43 spinal disease 10.6 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR149
44 retinal cancer 10.6 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR125A
45 larynx cancer 10.6 MIR21 MIR196A1 MIR17 MIR149 MIR143 MIR125A
46 mouth disease 10.6 MIR9-1 MIR21 MIR196A1 MIR17 MIR145 MIR125A
47 ocular cancer 10.6 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR17 MIR143
48 vascular disease 10.6 TIMP1 PTGS2 MIR21 MIR199A1 MIR145 MIR143
49 bone cancer 10.6 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR149
50 autosomal genetic disease 10.6 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR125A

Graphical network of the top 20 diseases related to Stomach Disease:



Diseases related to Stomach Disease

Symptoms & Phenotypes for Stomach Disease

UMLS symptoms related to Stomach Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, dyspepsia, icterus, signs and symptoms, digestive, heartburn, gastrointestinal gas, stomach ache

Drugs & Therapeutics for Stomach Disease

Drugs for Stomach Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rebamipide Approved, Investigational Phase 4 90098-04-7
2
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
3
Propranolol Approved, Investigational Phase 4 525-66-6 4946
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
6
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
7
Pantoprazole Approved Phase 4 102625-70-7 4679
8 Neurotransmitter Agents Phase 4
9 Protective Agents Phase 4
10 Antioxidants Phase 4
11 Pharmaceutical Solutions Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Analgesics Phase 4
14 Adrenergic alpha-1 Receptor Antagonists Phase 4
15 Adrenergic alpha-Antagonists Phase 4
16 Anti-Arrhythmia Agents Phase 4
17 Adrenergic Antagonists Phase 4
18 Adrenergic beta-Antagonists Phase 4
19 Antihypertensive Agents Phase 4
20 Adrenergic Agents Phase 4
21 Hormones Phase 4
22 Calcium, Dietary Phase 4
23 Vasodilator Agents Phase 4
24 calcium channel blockers Phase 4
25 Acidophilus Phase 4
26 Bifidobacterium Phase 4
27 Antipyretics Phase 4
28 Anti-Ulcer Agents Phase 4
29 Antacids Phase 4
30 Gastrointestinal Agents Phase 4
31 Anti-Infective Agents Phase 4
32
Bismuth Phase 4 7440-69-9 16682734 105143
33 Bismuth tripotassium dicitrate Phase 4
34
Calcium Nutraceutical Phase 4 7440-70-2 271
35
Dexlansoprazole Approved, Investigational Phase 3 138530-94-6, 103577-45-3 9578005
36
Lansoprazole Approved, Investigational Phase 3 103577-45-3 3883
37
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
38
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
39 Cyclooxygenase Inhibitors Phase 3
40 Antirheumatic Agents Phase 3
41 Protein Kinase Inhibitors Phase 3
42 Antimetabolites Phase 3
43
Apatinib Phase 3 811803-05-1
44
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
45
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
46
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 9812414
47
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
48
Fluorouracil Approved Phase 2 51-21-8 3385
49
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
50
leucovorin Approved Phase 2 58-05-9 6006

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy Completed NCT00641004 Phase 4 Rebamipide and Esomeprazole
2 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
3 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
4 Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial Completed NCT03198871 Phase 4 Acetaminophen Injectable Product;Sodium Chloride 0.9%, Intravenous
5 Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study Recruiting NCT02476097 Phase 4 Esomeprazole: Nexium® 20mg, Astra Zeneca;Placebo
6 Phase IV, Multicenter, Open Label, Randomized Study in Parallel Groups To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol®) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Patients With NSAID Induced Gastropathy Terminated NCT02788123 Phase 4 bismuth tripotassium dicitrate;pantoprazole
7 Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Open-label Study) Completed NCT00745459 Phase 3 NPO-11
8 Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial Completed NCT02219529 Phase 3
9 Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection Not yet recruiting NCT04325633 Phase 3 1: Naproxen;2: Standard of care
10 A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer Not yet recruiting NCT03889626 Phase 3 Apatinib;Capecitabine
11 Gastric Preparation of Magnetic-controlled Capsule Endoscopy: A Prospective, Single Blinded and Randomized Controlled Trial Unknown status NCT02846155 Phase 2 simethicone;simethicone combined with pronase
12 A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments Completed NCT01576380 Phase 2 TKI258
13 A Double-center Self-controlled Comparative Study of the Magnetic-controlled Capsule Endoscopy Versus Standard Gastroscopy for Gastric Diseases Completed NCT01903629 Phase 1, Phase 2
14 Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) Recruiting NCT03064490 Phase 2 Pembrolizumab
15 EUS Guided Portal-systemic Pressure Gradient Measurement in Patients With Chronic Hepatitis. Recruiting NCT04633356 Phase 1, Phase 2
16 Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial. Recruiting NCT03549494 Phase 2
17 A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas Terminated NCT03122548 Phase 2
18 Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy Terminated NCT00142974 Phase 2 Tegaserod
19 A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression Recruiting NCT03255070 Phase 1 ARX788
20 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing: a Population-based Randomized Study Unknown status NCT01741363
21 CMV Criteria in the Detection of Gastric Diseases Using Linked Color Imaging Unknown status NCT03092414
22 Gastric Emptying: in Vivo Studies in Healthy Volunteers (Using Scrambled Egg and Porridge) to Determine Reliable Normal Ranges Unknown status NCT02994472
23 Indications and Outcomes of Gastrointestinal Endoscopic Ultrasound in Tanta-Egypt: Initial Experience. Unknown status NCT03267355
24 Automatic Real-time Diagnosis of Gastric Mucosal Disease Using Probe-based Confocal Laser Endomicroscopy With Artificial Intelligence Unknown status NCT03784209
25 Comparison of Effectiveness of "Sekanjabin e Safarjali" (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction Unknown status NCT02179775 propranolol;Quince's oxymel;placebo
26 Risk Factors for Gastric Disease in Pediatric H. Pylori Completed NCT00212225
27 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859
28 Repetitive Position Change After Dimethicone Premedication Improves Gastric Cleanliness for Magnetically Controlled Capsule Endoscopy: a Single-blind, Randomized Controlled Trial Completed NCT03514966
29 Study of the Exhaled Breath and Salivary Metabolites of Patients With Malignant or Benign Gasctric Lesions Completed NCT01420588
30 IMPACT OF ALVEOLAR RECOVERY MANEUVER ON PULMONARY FUNCTION AND RESPIRATORY MECHANISM IN PATIENTS SUBMITTED TO BARIATRIC SURGERY ASSESSED BY ELECTROMAT IMPEDANCE TOMOGRAPHY: A RANDOMIZED CLINICAL TRIAL Completed NCT03476863
31 Optimization of Simethicone Administration Strategy Before Esophagogastroscopy Completed NCT03776916
32 Transoral Removal of Specimen During Laparoscopic Gastric Resection Completed NCT04111393
33 Non-invasive Methods to Predict Portal Hypertensive Gastropathy in Patients With Cirrhosis Completed NCT03513900
34 Evaluation of a Novel Endoscopic Polypectomy Device in Excised Human Colon and Gastric Tissue. Completed NCT01322737
35 Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses Completed NCT02105506 Tachosil patch
36 A Pilot Study to Investigate Whether Intragastric Pressure During Food Intake Can be Measured Using an Intragastric Bag in Healthy Volunteers Completed NCT03500887
37 A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time Completed NCT00128284
38 A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time - In Subjects Over 65 Years of Age Completed NCT00682877
39 Drop in Gastroscopy - Experience After 9 Months Completed NCT00977678
40 Study of Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy Recruiting NCT04068480
41 A Randomized Controlled Trial Comparing Endoscopic Ultrasound Evaluation Versus Esophagogastroduodenoscopy in the Diagnosis of Portal Hypertension in Cirrhotic Patients Recruiting NCT04191369
42 The Usage of Soda-Water in Gastric Preparation for Magnetically Controlled Capsule Endoscopy: A Prospective,Single Center,Randomized Controlled Study Not yet recruiting NCT04479423
43 An Exploratory Assessment of Small Bowel Transit Time and Small Bowel Bacterial Overgrowth Using the SmartPill Capsule Terminated NCT00577772 Xifaxan
44 Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription for Gastropathy Prevention Due to Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Primary Health Care Withdrawn NCT01128127

Search NIH Clinical Center for Stomach Disease

Cochrane evidence based reviews: stomach diseases

Genetic Tests for Stomach Disease

Anatomical Context for Stomach Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Stomach Disease:

19
Stomach

MalaCards organs/tissues related to Stomach Disease:

40
Small Intestine, Liver, Colon, Spleen, Smooth Muscle, Tongue, Thymus

Publications for Stomach Disease

Articles related to Stomach Disease:

(show top 50) (show all 452)
# Title Authors PMID Year
1
Serological Biomarker Test (GastroPanel®) in the Diagnosis of Functional Gastric Disorders, Helicobacter pylori and Atrophic Gastritis in Patients Examined for Dyspeptic Symptoms. 42
33517286 2021
2
INFLUENCE OF SYSTEMATIC TAKING BLOCKERS OF H2-HISTAMINE RECEPTORS ON THE DEGREE OF SEMINATION OF GASTRIC MUCOSA WITH HELICOBACTER PYLORI INFECTION OF PATIENT WITH CHRONIC NON - ATROPHIC GASTRITIS. 42
33454691 2020
3
DYNAMICS OF GASTRIN LEVEL IN PATIENTS WITH DIABETES MELLITUS 2 TYPE AND CHRONIC GASTRITIS AFTER HELICOBACTER PYLORI ERADICATION THERAPY. 42
33454693 2020
4
[Stomach disease and ghrelin]. 54 61
15506414 2004
5
Associations between pediatric asthma and adult non-communicable diseases. 61
33065756 2021
6
GCdiscrimination: identification of gastric cancer based on a milliliter of blood. 61
32010933 2021
7
Acute abdominal disease with nonspecific symptoms in the elderly: A case series. 61
33596513 2021
8
Investigation of Radon Sources, Health Hazard and Risks assessment for children using analytical and geospatial techniques in District Bannu (Pakistan). 61
33428859 2021
9
Banxia Xiexin Decoction in the treatment of chronic atrophic gastritis: A protocol for systematic review and meta-analysis. 61
33080670 2020
10
Laser-induced fluorescence diagnosis of stomach tumor. 61
31953738 2020
11
N-Alkylamides from Piper longum L. and their stimulative effects on the melanin content and tyrosinase activity in B16 melanoma cells. 61
30623685 2020
12
Facile synthesis of ratiometric fluorescent carbon dots for pH visual sensing and cellular imaging. 61
32456917 2020
13
Risk assessment via genotoxicity, metabolism, apoptosis, and cell growth effects in a HepG2/C3A cell line upon treatment with Rubus rosifolius (Rosaceae) leaves extract. 61
32568621 2020
14
High-Salt Diet-Induced Gastritis in C57BL/6 Mice is Associated with Microbial Dysbiosis and Alleviated by a Buckwheat Diet. 61
32032975 2020
15
[Study on medication regularity of chronic atrophic gastritis in Beijing-Tianjin-Hebei region based on latent structure model]. 61
32489051 2020
16
Characteristics analysis of the complete Wurfbainia villosa chloroplast genome. 61
32255937 2020
17
[Pharmacological and clinical feature of rebamipide: new therapeutic targets]. 61
32598727 2020
18
Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). 61
32161305 2020
19
Geranium thunbergii extract-induced G1 phase cell cycle arrest and apoptosis in gastric cancer cells. 61
32158613 2020
20
Gastric Stem Cells: Physiological and Pathological Perspectives. 61
33043003 2020
21
Initiatives for a Healthy Stomach. 61
31776804 2019
22
Significant of adiponectin in gastropathy: Case-controlled study. 61
31641495 2019
23
Two novel transcriptional reporter systems for monitoring Helicobacter pylori stress responses. 61
31669286 2019
24
[Professor CHU Hao-ran's experience of acupuncture and moxibustion of regulating spleen-stomach and differentiating meridians-collaterals]. 61
31724359 2019
25
Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis. 61
31368293 2019
26
History of gastroesophageal reflux disease in patients with suspected coronary artery disease. 61
30993440 2019
27
METALLOTHIONEIN-2A (RS1610216&RS28366003) GENE POLYMORPHISMS AND THE RISK OF STOMACH ADENOCARCINOMA. 61
31721970 2019
28
Evaluation of hepatotoxicity potential of a potent traditional Tibetan medicine Zuotai. 61
30580024 2019
29
[Risk factors of oral Helicobacter pylori infection among children in two kindergartens in Suzhou and the effects of oral cleaning on reducing oral Helicobacter pylori infection]. 61
30854823 2019
30
Investigation on correlations of serum IL-26 with diagnosis and staging of gastric cancer. 61
30941972 2019
31
[Effect of modified Zhengqi Powder in treating chronic gastritis and on patients' life quality and inflammatory factors]. 61
30868830 2019
32
A Clinical Trial on Oral H. pylori Infection of Preschool Children. 61
30610045 2018
33
[Analysis on medication regularity and action mechanism of Tibetan medicine in treatment of spleen and stomach diseases based on data mining and integrated pharmacology]. 61
30200743 2018
34
Effect of Pistacia atlantica kurdica gum on diabetic gastroparesis symptoms: a randomized, triple-blind placebo-controlled clinical trial. 61
30128090 2018
35
Pistacia atlantica Desf. A review of its traditional uses, phytochemicals and pharmacology. 61
30364651 2018
36
Calycophyllum spruceanum BENTH ameliorates acute inflammation in mice. 61
29567276 2018
37
[Research progress of Tibetan medicine "Zha-xun"]. 61
29751700 2018
38
Levels of malondialdehyde in the gastric juice: Its association with Helicobacter pylori infection and stomach diseases. 61
29315971 2018
39
Dihydroorotate Dehydrogenase as a Target for the Development of Novel Helicobacter pylori-Specific Antimicrobials. 61
29491257 2018
40
In situ quantification and evaluation of ClO-/H2S homeostasis in inflammatory gastric tissue by applying a rationally designed dual-response fluorescence probe featuring a novel H+-activated mechanism. 61
28394381 2017
41
[Expressions of MMP-7 and TIMP-1 in Chronic Stomach Disease Patients with Different Syndromes of Chinese Medicine]. 61
30695426 2017
42
Application of Micellar Extraction for Isolation of Famotidine from Aqueous Samples Prior to its Chromatographic Determination. 61
29200812 2017
43
Serum Pepsinogen Levels Are Correlated With Age, Sex and the Level of Helicobacter pylori Infection in Healthy Individuals. 61
27865295 2016
44
Image enhancement based on in vivo hyperspectral gastroscopic images: a case study. 61
27206742 2016
45
Trichloromethane fraction of Incarvillea compacta induces lytic cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric cancer AGS cells. 61
27595569 2016
46
Ethnobotany, chemical constituents and biological activities of the flowers of Hydnora abyssinica A.Br. (Hydnoraceae). 61
27209704 2016
47
Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. 61
26709179 2016
48
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. 61
25986943 2016
49
Effect of propolis in gastric disorders: inhibition studies on the growth of Helicobacter pylori and production of its urease. 61
27233102 2016
50
[Midnight-noon ebb-flow acupuncture at stomach meridian of foot-yangming: a fMRI study]. 61
26964172 2015

Variations for Stomach Disease

Expression for Stomach Disease

Search GEO for disease gene expression data for Stomach Disease.

Pathways for Stomach Disease

Pathways related to Stomach Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 PTGS2 MIR9-1 MIR30A MIR21 MIR20A MIR199A1
2 11.63 MIR9-1 MIR21 MIR129-1 MIR125A
3 11.38 TIMP1 PTGS2 MMP7
4 11.18 MIR30A MIR20A MIR17 MIR106A
5 10.44 MIR199A1 MIR145

GO Terms for Stomach Disease

Cellular components related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 TIMP1 MMP7 MIR30A MIR21 MIR20A MIR199A1
2 extracellular vesicle GO:1903561 9.1 MIR106A MIR125A MIR17 MIR20A MIR21 MIR30A

Biological processes related to Stomach Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.94 MIR21 MIR20A MIR17 MIR125A
2 negative regulation of cell migration GO:0030336 9.87 MIR145 MIR149 MIR21 MIR9-1
3 negative regulation of inflammatory response GO:0050728 9.85 GHRL MIR145 MIR149 MIR20A
4 positive regulation of angiogenesis GO:0045766 9.85 MIR143 MIR199A1 MIR20A MIR21 MIR30A
5 negative regulation of interleukin-6 production GO:0032715 9.8 MIR149 MIR125A GHRL
6 negative regulation of angiogenesis GO:0016525 9.77 GHRL MIR125A MIR143 MIR145 MIR21
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR21 MIR20A MIR17
8 negative regulation of stress fiber assembly GO:0051497 9.71 MIR149 MIR20A MIR21
9 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.71 MIR149 MIR196A1 MIR199A1 MIR20A
10 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.7 MIR143 MIR20A MIR21
11 negative regulation of cardiac muscle hypertrophy GO:0010614 9.65 MIR21 MIR145
12 regulation of smooth muscle contraction GO:0006940 9.65 MIR145 MIR143
13 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.65 MIR106A MIR17 MIR20A
14 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.64 MIR199A1 MIR17
15 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.63 MIR21 MIR125A
16 miRNA mediated inhibition of translation GO:0035278 9.63 MIR106A MIR145 MIR17 MIR20A MIR21 MIR9-1
17 positive regulation of metalloendopeptidase activity GO:1904685 9.62 MIR21 MIR17
18 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
19 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.62 MIR145 MIR199A1 MIR20A MIR21
20 negative regulation of metallopeptidase activity GO:1905049 9.61 TIMP1 MIR199A1
21 negative regulation of STAT cascade GO:1904893 9.61 MIR149 MIR125A
22 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR17 MIR199A1 MIR20A
23 gastric acid secretion GO:0001696 9.6 HRH2 GHRL
24 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.59 MIR21 MIR17
25 aorta smooth muscle tissue morphogenesis GO:0060414 9.58 MIR143 MIR145
26 regulation of phenotypic switching GO:1900239 9.56 MIR143 MIR145
27 negative regulation of interleukin-16 production GO:0032699 9.51 MIR125A MIR145
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.49 MIR143 MIR145
29 gene silencing by miRNA GO:0035195 9.44 MIR106A MIR125A MIR129-1 MIR143 MIR145 MIR149
30 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.43 MIR143 MIR17 MIR20A
31 negative regulation of vascular endothelial growth factor production GO:1904046 9.35 MIR106A MIR125A MIR17 MIR199A1 MIR20A

Molecular functions related to Stomach Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 MIR106A MIR125A MIR143 MIR145 MIR17 MIR20A
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.44 MIR9-1 MIR30A MIR21 MIR20A MIR199A1 MIR196A1
3 RNA polymerase II complex binding GO:0000993 9.33 MIR20A MIR145 MIR125A

Sources for Stomach Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....